Vallon Pharmaceuticals, Inc. (VLON)
$0.4
-0.06 (-13.04%)
Rating:
Recommendation:
-
| Symbol | VLON |
|---|---|
| Price | $0.4 |
| Beta | -1.149 |
| Volume Avg. | 8.09M |
| Market Cap | 5.393M |
| Shares () | - |
| 52 Week Range | 0.2054-16.5 |
| 1y Target Est | - |
| DCF Unlevered | VLON DCF -> | |
|---|---|---|
| DCF Levered | VLON LDCF -> | |
| ROE | -219.04% | Strong Sell |
| ROA | -169.17% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 77.28% | Buy |
| P/E | -0.03 | Neutral |
| P/B | 1.73 | Strong Buy |
Latest VLON news
About
Download (Excel)Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.